|Dr. Malcolm L. McColl BVSc (Hons), MBA||MD, CEO & Exec. Director||564.28k||N/A||N/A|
|Mr. Robert Vickery||Chief Financial Officer||198.12k||N/A||N/A|
|Prof. Darren Shafren B.Sc (Hons I) Ph.D.||Chief Scientific Officer||364.7k||N/A||N/A|
|Dr. Jennifer Rosenthal Ph.D.||Director of Regulatory Affairs||237.75k||N/A||N/A|
|Ms. Rae Saltzstein||Director of CMC Operations||66.01k||N/A||N/A|
Viralytics Limited, a biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies in Australia and internationally. The company's lead investigational product is CAVATAK, a proprietary formulation of an oncolytic common cold virus that is in Phase Ib clinical trials for the treatment of melanoma, and lung and bladder cancer; Phase II clinical trials for the treatment of late stage melanoma; and in pre-clinical studies for the treatment of prostate and breast cancer, multiple myeloma, pancreatic cancer, malignant glioma, acute myeloid leukemia, and chronic lymphocytic leukemia. It is also developing EVATAK to treat ovarian, prostate, and gastric cancer. The company was formerly known as Psiron Ltd. and changed its name to Viralytics Limited in December 2006. Viralytics Limited is headquartered in Sydney, Australia.
Viralytics Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.